Introduction {#Sec1}
============

Hypoglycemia is a common and serious side effect associated with glucose-lowering therapies. Hypoglycemia occurs frequently in insulin-treated patients, and prevalence is higher in patients with type 1 diabetes (T1D) than type 2 diabetes (T2D), but increases in frequency in T2D with disease duration as treatment intensifies \[[@CR1]--[@CR3]\]. Hypoglycemia is a major burden for the healthcare sector and society, due to the treatment cost and the associated lost productivity \[[@CR4]--[@CR6]\]; it is also a burden for patients, resulting in fear and anxiety, and disruption to their sleep, and their domestic and social life \[[@CR4], [@CR7], [@CR8]\]. Moreover, hypoglycemia is associated with death, adverse cardiovascular outcomes, dementia, falls, and fractures \[[@CR9]\]. Furthermore, hypoglycemia can occur suddenly and with varying severity \[[@CR4], [@CR9]\]. Severe hypoglycemic events (SHEs, requiring third-party assistance) may require hospitalization and inpatient care, leading to significant resource use and costs \[[@CR10]--[@CR12]\].

The aim of this study was to quantify the resource use and expense associated with an SHE in adult patients with diabetes, using the Maccabi Healthcare Services (MHS) database registry. The majority of studies investigating resource use following hypoglycemia provide retrospective data on resource use after an event, with many only including patients who report resource use. This study is unique in that data were collected before and after an SHE for a designated time period, enabling assessment of the change in resource use after an SHE. The time period under consideration for this analysis was 1 month pre-SHE and 1 month post-SHE.

Methods {#Sec2}
=======

MHS is the second-largest Health Management Organization (HMO) in Israel, serving 25% of the country's total population with approximately two million members. Since 1997, information on all members' interactions with MHS has been collected, including diagnoses, visits to primary and secondary care physicians, visits to outpatient clinics, hospitalizations, laboratory tests, and purchased and dispensed medications.

This observational, retrospective, non-interventional, cohort study analyzed de-identified patients' electronic medical record (EMR) data to compare resource use 1 month before and after the date that the index SHE was reported. The inclusion criteria for the MHS diabetes registry have been described previously \[[@CR13], [@CR14]\]. Briefly, the registry used criteria defined by the American Diabetes Association and included any patient with one or more of the following: HbA~1c~ ≥7.25%, blood glucose (BG) ≥11.1 mmol/L, a preceding diagnosis of diabetes \[identified using International Classification of Diseases version 9 (ICD-9) codes\] together with a measurement of HbA~1c~ ≥6.5% or BG \>6.9 mmol/L. The diabetes registry also included those who purchased ≥2 monthly packs of anti-hyperglycemic medication during a 6-month period. The MHS diabetes registry was created for clinical purposes and its data are routinely updated by the patient's physicians, to maintain a very high level of validity. Patients were excluded if they were \<18 years of age, were diagnosed with diabetes for \<12 months, had \<12 months' follow-up after their SHE, or if their type of diabetes was unknown. Data are presented for 1 month pre- and 1 month post-SHE. Data were also collected for 1 week and 12 months pre- and post-index date to conduct sensitivity analyses (data not shown).

Patients were included in this analysis if they had at least one SHE, identified by ICD-9 codes in the MHS registry between January 1, 2005 and April 30, 2013. Study index date (baseline) was defined as the earliest date of SHE diagnosis after a 12-month SHE-free period. This analysis considers data collected during 1 month before and after the SHE.

Data retrieved for this study included sociodemographic details, diabetes duration, body mass index (BMI), HbA~1c~, hypertension and cardiac comorbidities, and healthcare services utilization. Utilization data included hospitalizations, emergency department visits, outpatient visits and laboratory, pathology, radiology and imaging visits, medication, and purchases of self-measured blood glucose (SMBG) strips. The BMI value was the value taken nearest to the SHE (before or after it). HbA~1c~ value was the most recent result before the SHE. Socioeconomic status was based on residential socioeconomic index, ranging from 1 (lowest) to 20 (highest). In the patient records where diabetes type was not recorded, a classification of T1D was made if the patient was using insulin or had a positive glutamic acid decarboxylase (GAD) or islet cell antibody, and was under the age of 40 years. A classification of T2D was made if the patient was not using insulin for at least 1.5 years or had a positive C-peptide test. In other cases, the diabetes type was classified as unknown and the patient was excluded from the analysis.

Costs of different healthcare services were taken from the Israeli Ministry of Health price list in Israeli new shekels and were converted to \$US dollars. Costs per patient represent mean values for all patients included in the study. The study was approved by MHS' ethics committee and performed in accordance with the Declaration of Helsinki \[[@CR15]\]. The study was performed according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) Statement for cohort studies \[[@CR16]\].

Statistical Analysis {#Sec3}
--------------------

Resource utilization and healthcare costs were compared in the time period (1 month) before and after index SHE. Continuous variables (length of hospital stay and healthcare expenditure) were compared using a paired Student's *t* test. Chi square (number of hospitalizations) and McNemar's tests (hospital visits comparison) were used to compare categorical variables. Wilcoxon signed-rank test was used to compare ordinal variables (the number of hospitalizations per patient and expense comparisons). A Kruskal--Wallis test was used to compare between-group differences following stratification by BMI and socioeconomic status, and a Mann--Whitney test was used to compare insulin-treated versus non-insulin-treated groups. Statistical significance was set at *P* \< 0.05. All analyses were conducted using IBM SPSS software (IBM SPSS Statistics for Windows, version 21.0, released 2012, IBM Corporation, Armonk, NY, USA).

Results {#Sec4}
=======

Study Population {#Sec5}
----------------

A total of 3975 patients were eligible for inclusion in the study; their characteristics at index/time of SHE are summarized in Table [1](#Tab1){ref-type="table"}. Overall, 7.1% of patients in the study were categorized as T1D (*n* = 284), and 92.9% as T2D (*n* = 3691). At index, 95.4% of patients with T1D and 32.8% of patients with T2D were insulin treated, 3.5% with T1D and 70.4% with T2D were treated with oral antidiabetic drugs that could cause hypoglycemia (sulfonylureas or meglitinides), and 7.7% with T1D and 76.4% with T2D used oral drugs known to cause hypoglycemia only rarely (metformin, gliptins, glitazones, and acarbose). During 9 years of the study, there were only slight and insignificant differences in the number of SHEs reported by patients with diabetes in the registry each year.Table 1Study population characteristicsCharacteristicsT1DT2D*n*2843691Age, years29.8 ± 6.767.1 ± 11.7Males, *n* (%)149 (52.5)1756 (47.6)Duration of diabetes, years, *n* (%) \<597 (34.2)938 (25.4) 5--9131 (46.1)1824 (49.4) 10+56 (19.7)929 (25.2)BMI, kg/m^2^25.5 ± 4.629.9 ± 5.6HbA~1c~, % (most recent prior to SHE)7.9 ± 1.87.3 ± 1.5Cardiac comorbidity---yes, *n* (%)14 (4.9)1653 (44.8)Hypertension comorbidity---yes, *n* (%)25 (8.8)2914 (78.9)Hospitalization a week around index date, *n* (%)47 (16.5)973 (26.4)Socioeconomic status^a^11.1 ± 4.211.3 ± 4.2Fractures 1 month around SHE, *n* (%)3 (1.1)79 (2.1)Additional SHE within 12 months of index, *n* (%) 152 (18.3)661 (17.9) 216 (5.6)173 (4.7) 316 (5.7)159 (4.3)Data are mean ± standard deviation, unless otherwise specified*BMI* body mass index, *SHE* severe hypoglycemic event, *T1D* type 1 diabetes, *T2D* type 2 diabetes^a^On a scale from 1 (lowest) to 20 (highest)

Hospital Visits {#Sec6}
---------------

In the month following an SHE, 25% (*n* = 992) of the study population were hospitalized and 10% (*n* = 401) visited the emergency department. The number of hospital admissions increased significantly (by 95% for T1D and by 127% for T2D, *P* \< 0.001) in the month following the SHE (Table [2](#Tab2){ref-type="table"}) compared with the month before the SHE. Additionally, the proportion of patients with 1, 2, or 3+ hospital admissions also increased significantly during this period versus the previous month (Fig. [1](#Fig1){ref-type="fig"}). The proportion of patients with T1D hospitalized on one occasion increased 1 month post-SHE but there was no increase in the number of patients requiring two or three hospitalizations. In patients with T2D, there was an increase in the proportion of patients with 1, 2, and 3+ hospitalizations 1 month post- versus 1 month pre-SHE.Table 2Number of hospitalization episodesTotal no. of hospitalizations1 month pre-SHE1 month post-SHEChange (%)*P* valueT1D Total68234595\<0.001 Non-surgical65224395\<0.001 Surgical3121000.861T2D Total15984881110127\<0.001 Non-surgical14604301030139\<0.001 Surgical1385880370.075Total number of hospitalizations divided according to type of procedure (non-surgical or surgical) and diabetes type. Analysis conducted using a Chi-square test*SHE* severe hypoglycemic event, *T1D* type 1 diabetes, *T2D* type 2 diabetesFig. 1Proportion of patients with **a** T1D and **b** T2D who had hospital admissions 1 month pre-SHE versus 1 month post-SHE. **a** *P* \< 0.009; **b** *P* \< 0.001 for comparison of number of hospitalizations pre-SHE versus post-SHE (Wilcoxon test). *SHE* severe hypoglycemic event, *T1D* type 1 diabetes, *T2D* type 2 diabetes

Of the patients admitted to hospital pre- and/or post-SHE (T1D: *n* = 59, 1.4%; T2D: *n* = 1214, 30.5%), the overall mean duration of stay was significantly longer during the month post- versus pre-SHE in both patients with T1D and T2D (T1D: 2.08 vs. 0.88 days, *P* = 0.036; T2D: 4.17 vs. 1.45 days, *P* \< 0.001; Table [3](#Tab3){ref-type="table"}). The mean increase in hospital stay post-SHE was longer in patients with T1D and T2D admitted for non-surgical procedures and patients with T2D admitted for surgical procedures, but not patients with T1D admitted for surgical procedures (Table [3](#Tab3){ref-type="table"}). Of the 1273 patients who were hospitalized in the month pre- or post-SHE, 148 (3.7% of the total study population; 11.6% of the hospitalized patients) were hospitalized both in the month pre- and the month post-SHE. The mean duration of stay in patients with T2D hospitalized pre- and post-SHE was significantly longer in the month post-SHE compared with the month pre-SHE (9.36 vs. 5.84 days, *P* = 0.002), whereas there was no significant difference in those with T1D (Table [3](#Tab3){ref-type="table"}).Table 3Mean duration (days) of hospital stay per patient 1 month pre- and 1 month post-SHENumber of patients1 month pre-SHE1 month post-SHEChange (%)*P* valueAll hospitalized patients T1D  Total590.88 ± 2.322.08 ± 3.451360.036  Non-surgical57^a^0.91 ± 2.362.21 ± 3.461420.041  Surgical3^a^0.000.66 ± 1.15--0.423 T2D  Total12141.45 ± 3.284.17 ± 8.40187\<0.001  Non-surgical1146^a^1.29 ± 2.713.95 ± 7.68206\<0.001  Surgical138^a^2.07 ± 5.043.85 ± 7.97850.044Patients hospitalized both pre- and post-SHE T1D25.50 ± 0.707.00 ± 7.07270.830 T2D1465.84 ± 5.719.36 ± 13.29600.002Data are mean ± standard deviation for hospitalized patients only. *P* values are based on a paired *t* test, which assumes independence between groups*SHE* severe hypoglycemic event, *T1D* type 1 diabetes, *T2D* type 2 diabetes^a^Some patients had both surgical and non-surgical procedures during the time period assessed

In the month following an SHE, the total number of outpatient visits increased significantly from 744 to 1022 (37% increase, *P* \< 0.001) in patients with T1D, and from 10,626 to 15,685 (47% increase, *P* \< 0.001) in patients with T2D. The greatest increases were in visits to endocrinologists, nurses, and dieticians (Table [4](#Tab4){ref-type="table"}). There was a non-significant increase in outpatient pathology, radiology, and imaging visits, and a significant increase in the number of lab tests conducted following an SHE in patients with T2D (Table [4](#Tab4){ref-type="table"}). There was also a significant increase in the number of medication purchases post-SHE, including a 61% increase in SMBG sticks purchases in patients with T2D (*P* \< 0.001) and a 20% increase in diabetic medication purchases in patients with T1D (*P* = 0.014; Table [4](#Tab4){ref-type="table"}).Table 4Number of outpatient visits, tests and medication pack purchases 1 month pre- and 1 month post-SHE1 month pre-SHE1 month post-SHEChange (%)*P* valueOutpatient visits T1D  Endocrinology7814788\<0.001  Nursing care5279510.023  Dietician4271690.008  Mental care1324840.100  General medicine35953448\<0.001  Physiotherapy171851.000  Cardiology41−750.375  Internal medicine899560.712  Ophthalmology4023--420.044  Surgery132--840.007  Orthopedics3728--240.321  Total744102237\<0.001 T2D  Endocrinology346960177\<0.001  Nursing care747128772\<0.001  Dietician34155663\<0.001  Mental care21030746\<0.001  General medicine6079932653\<0.001  Physiotherapy59574725\<0.001  Cardiology148185250.049  Internal medicine832962150.002  Ophthalmology50655690.133  Surgery36737620.769  Orthopedics455423--70.295  Total10,62615,68547\<0.001Outpatient tests T1D  Pathology, radiology and imaging94--1250.166  Lab tests (all)122110--90.470  HbA~1c~ tests8368--180.225 T2D  Pathology, radiology and imaging203240150.073  Lab tests (all)2221259016\<0.001  HbA~1c~ tests1019111790.036Medication packs T1D  Total medication11701313120.045  Diabetic medication493594200.014  SMBG sticks492584180.091 T2D  Total medication40,71144,89510\<0.001  Diabetic medication8494889340.069  SMBG sticks1774286461\<0.001Outpatient visits and outpatient tests comparisons were conducted using a McNemar's test. Medication packs comparisons were conducted using a Wilcoxon test*SHE* severe hypoglycemic event, *SMBG* self-measured blood glucose, *T1D* type 1 diabetes, *T2D* type 2 diabetes

Cost of Treatment {#Sec7}
-----------------

The increase in frequency and duration of hospitalization and the frequency of outpatient visits resulted in a significant increase in the total costs, hospital costs, and outpatient costs in the month following an SHE compared with the month before (Fig. [2](#Fig2){ref-type="fig"}). The total expense per patient per month increased by 46% (*P* = 0.001) from \$485 to \$708 for T1D and 87% (*P* \< 0.001) from \$601 pre-SHE to \$1121 post-SHE for T2D. The greatest expense, and the greatest increase in expense, was hospitalization, with an increase per patient per month from \$112 to \$312 (+179%, *P* = 0.003) in T1D, and from \$265 to \$706 (+166%, *P* \< 0.001) in T2D. Additionally, there was a significant increased expenditure of 37% in T1D and 46% in T2D for visits to healthcare specialists, and 34% in T2D for emergency department visits in the month following an SHE compared with the month pre-SHE (Fig. [2](#Fig2){ref-type="fig"}). In this analysis, there was no significant change in the expenses associated with pathology, radiology, and imaging or lab tests.Fig. 2Healthcare costs per patient 1 month pre- and 1 month post-SHE total costs for **a** T1D and **b** T2D, and breakdown of outpatient costs for **c** T1D and **d** T2D. Cost comparisons conducted using Wilcoxon test. *SHE* severe hypoglycemic event, *SMBG* self-measured blood glucose, *T1D* type 1 diabetes, *T2D* type 2 diabetes

As additional sensitivity analyses, healthcare expenses were also stratified by BMI, socioeconomic index, whether or not the patient was insulin treated, Charlson comorbidity index, and HbA~1c~ (Table [5](#Tab5){ref-type="table"}). There were no significant differences in expenses across BMI categories, socioeconomic status, HbA~1c~ levels, or insulin treatment in both patients with T1D and T2D. In patients with T2D, there was a significant increase in expenses for Charlson index categories, with patients with Charlson index of +4 having a 91% increase in mean expenses per patient in the month post-SHE versus pre-SHE. No significant differences for Charlson index categories were detected for patients with T1D (Table [5](#Tab5){ref-type="table"}).Table 5Total expenses per patient stratified by BMI, socioeconomic status, and insulin useCosts US \$Pre-SHE vs. post-SHEBetween-group comparison1 month pre-SHE1 month post-SHEChange (%)*P* value^b^*P* valueT1D BMI, kg/m^2^ (*n*)\<25 (172)441740670.0040.865^c^26--30 (80)571677180.173\>31 (30)531646210.192 Socioeconomic status^a^ (*n*)Low (37)638708100.8390.680^c^Medium (115)596769290.051High (72)333656960.037 Insulin use (*n*)Yes (271)494677360.0010.883^d^No (13)29813663570.650 Charlson comorbidity index^e^ (*n*)Low (166)448612360.0080.385^c^Medium (88)431730690.212High (30)8491177380.072 HbA~1c~ (*n*)≤7% (99)538776440.0610.984^c^7--9% (122)420541280.013\>9% (61)530899690.227T2D BMI, kg/m^2^ (*n*)\<25 (908)652127194\<0.0010.574^c^26--30 (1311)53899083\<0.001\>31 (1358)564100778\<0.001 Socioeconomic status^a^ (*n*)Low (563)59095561\<0.0010.528^c^Medium (1600)603118796\<0.001High (1057)589113993\<0.001 Insulin use (*n*)Yes (1210)687136398\<0.0010.187^d^No (2481)558100379\<0.001 Charlson comorbidity index^e^ (*n*)Low (776)31555275\<0.001\<0.001^c^Medium (1056)48386578\<0.001High (1859)787150491\<0.001 HbA~1c~ (*n*)≤7% (1870)600115692\<0.0010.882^c^7--9% (1382)568103682\<0.001\>9% (436)712124374\<0.001*BMI* body mass index, *SHE* severe hypoglycemic event, *T1D* type 1 diabetes, *T2D* type 2 diabetes^a^Socioeconomic status: Residential socioeconomic index ranging from 1 (lowest) to 20 (highest); low 1--6; medium 7--13; high 14--20^b^Statistical analysis based on a Wilcoxon signed-rank test^c^Statistical analysis based on a Kruskal--Wallis test^d^Statistical analysis based on a Mann--Whitney test^e^Charlson comorbidity index: comorbidity index ranging from 1 (lowest) to 16 (highest); low ≤1; medium 2--3; high ≥4

Discussion {#Sec8}
==========

In this real-world, non-interventional analysis of data from a large-scale diabetes registry, severe hypoglycemia was associated with increased use of healthcare services and resources, resulting in a significant increase in healthcare expenses in the month following an SHE compared with the month pre-SHE. These results indicate that in the month following an SHE, patients have significantly more frequent and prolonged hospital admissions and outpatient visits versus the month pre-SHE. While it is recognized that factors other than the SHE could influence the data over the time period, the non-significant change in pathology, radiology, and imaging visits would suggest that there was no change in concomitant serious illnesses.

The increase in the proportion of patients with 1, 2, and 3+ hospitalizations and the increase in length of hospital stay 1 month post- versus 1 month pre-SHE were higher for patients with T2D compared with T1D, possibly due to the higher rate of comorbidities and greater age in these populations. It is possible that patients with T1D and their carers may also have more experience at coping with SHEs, and therefore be less inclined to go to the hospital, compared with patients with T2D who may not be insulin treated or have been treated with insulin for a shorter duration, and therefore have experienced fewer SHEs. It should also be noted that the number of patients in the T1D category was smaller than in the T2D category, and this may partly explain why the results did not reach significance. However, other studies have also shown that hospitalization for severe hypoglycemia is more frequent in patients with T2D compared with T1D \[[@CR10], [@CR17]\]. These include a study of the resource use associated with severe hypoglycemia in insulin-treated patients with diabetes from a large clinical trial program, which showed that severe hypoglycemia often results in the use of emergency services or ambulance calls and in hospital treatment \[[@CR17]\]. Severe hypoglycemia is recognized as a common cause of hospitalization in elderly patients with diabetes and those with comorbidities \[[@CR18], [@CR19]\], and in one study accounted for 94.6% of all endocrine emergency hospitalizations in older patients \[[@CR20]\].

The results presented here are consistent with those from several other studies reporting the extensive resource use and cost implications of severe hypoglycemia for healthcare providers/payers. Although the costs vary depending on the countries included and their healthcare systems \[[@CR6], [@CR10]--[@CR12], [@CR17], [@CR21]\], together they illustrate that hypoglycemia is a significant burden and that efforts to minimize it are likely to reduce the economic burden of diabetes.

Previous studies into hypoglycemia-related resource use did not compare the before and after costs for a specific population of patients. This study benefits from the pre- and post-event design, allowing for elucidation of the change in resource use and expenses to be compared, while correcting for background resource use. In support of the robustness of these results, sensitivity analyses conducted with 1 week and 1 year pre- and post-SHE data showed similar results (data not shown). The study also benefits from the level of detail captured and the size of the population included in the registry. Following the 1994 Israel National Health Act, MHS may not deny coverage to applicants on any grounds, including age or state of health, and thus these results are a representation of all sectors of the Israeli population, except for young adults aged 18--21 years, due to the high percentage of them being enlisted in the Israeli Defense Forces.

A limitation of this study is that the registry did not record the cause of SHEs or the reason why patients were hospitalized, so the primary reason for hospitalization may not have been related to diabetes or hypoglycemia in all cases. Some patients were hospitalized pre-SHE; however, in the patients who were hospitalized both pre- and post-SHE, the duration of stay was significantly increased post-SHE, so experiencing an SHE may have contributed to their longer hospital stay. The number of patients with T1D included in the analysis was low, and they may not be considered a representative sample of patients with T1D because of their age (\>18 years) and late diagnosis age (around the age of 20 years). It is also not known how many non-severe hypoglycemia events the study population experienced during the designated time period, or whether they contributed to the increase in resource use observed here; nonetheless, this should not affect the conclusion of the study. Furthermore, the patients' diabetes-related complications may also have contributed to resource use.

Conclusions {#Sec9}
===========

In conclusion, this real-world analysis of nearly 4000 patients with diabetes who experienced an SHE documents the healthcare resources used, and expenses associated with severe hypoglycemia. The frequency and length of hospital stay increased, the number of outpatient visits increased, and the cost of treatment increased in the month post-SHE compared with the month pre-SHE.

**Enhanced content**

To view enhanced content for this article go to <http://www.medengine.com/Redeem/A7B4F06002BC662B>.

This study and the associated article processing charges for publication were funded by Novo Nordisk. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. The authors take full responsibility for the content of the manuscript but are grateful to Adele Buss PhD and Daria Renshaw from Watermeadow Medical, an Ashfield Company, for medical writing and editing/submission support. This support was funded by Novo Nordisk A/S. Parts of this study have been published as abstracts and posters at the American Diabetes Association, 75th Annual Scientific Sessions, June 5--9, 2015, Boston, MA, USA and the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD), September 14--18, 2015, Stockholm, Sweden.

Disclosures {#FPar1}
===========

Dalit Goldstein has no financial disclosures to declare. Gabriel Chodick has received research support from Merck, AbbVie, Pfizer, and Medial Cancer Research. Varda Shalev has received research support from Maccabitech. Brian L. Thorsted is an employee and shareholder of Novo Nordisk A/S. Lisa Elliott is an employee of Novo Nordisk A/S. Avraham Karasik has served on advisory panels for Novo Nordisk A/S and Merck Sharp and Dohme, and as a consultant for, and received research support from, Novo Nordisk A/S, Merck Sharp and Dohme, and Boehringer-Ingelheim.

Compliance with Ethics Guidelines {#FPar2}
=================================

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was not required for this study.

Open Access {#d30e2673}
===========

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
